Kazia Therapeutics Ltd ADR (KZIA) Stock Analysis & Winston Score

Winston Score History

Kazia Therapeutics is a small Australian biotechnology company focused on developing drugs to treat brain cancer. Its main drug candidate is paxalisib, a pill designed to cross into the brain and slow the growth of glioblastoma, which is one of the deadliest and hardest-to-treat brain tumors. The company targets patients and oncologists in the medical community, and it has also licensed paxalisib to a Chinese partner for development in Asia.

Kazia makes no product revenue yet — it is a clinical-stage company that funds itself through licensing deals, grants, and by raising money from investors. It operates primarily out of Australia but runs clinical trials in the United States and other countries. With a market cap near zero and a deeply negative operating margin, the company burns cash while waiting for trial results. The key risk is that paxalisib must prove it works in late-stage clinical trials, or the company could run out of funding before reaching the market.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-99.2% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+79.5% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

1.4%ownership

Relatively low insider ownership

Cash Runway

~2 months

$4M cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

Kazia Therapeutics Ltd ADR has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-39.0%

Weak — -39.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-99.2%

Shrinking sales (-99.2% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-88072.4%

Burning cash (-88072.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.00

Conservative — low debt load (0.00)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial